StonklyGainz

OpGen Long - Possible FDA approval soon

Long
StonklyGainz Aktualisiert   
NASDAQ:OPGN   OpGen, Inc.
OpGen has gone through a complete accumulation cycle in anticipation of FDA approval for their AMR gene panel. During the last few days of broad market pull back, we see above average volume the downside holding support at $2.80 - $2.90. RSI on the 1HR is approaching oversold. SP has fallen through 50EMA we could possibly see a correction back to uptrend support. 1HR resistance around $3.20 $3.50 $4.00 $4.50 $4.80

Recent Corporate Overview published on 2/16/21

Google - "wyckoff accumulation schematic 1" for more information on accumulation cycle
Trade ist aktiv:
Current average $2.937

Point and Figure chart has bullish price objective of $6.25
Kommentar:
Recent news
3/1 - receives regulatory approval of the Curetis Unyvero System as an in vitro diagnostics ((IVD)) instrument system in China.
3/2 - Analysts raise price target to $7.00
Kommentar:
Posted update in comments by accident. Also to add, 3.1M new warrants issued to the previous holder at an exercise price of $3.56
Haftungsausschluss

Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.